Eli Lilly: Tirzepatide's Winning Streak Continues

Scott Olson/Getty Images News Eli Lilly and Company's (LLY) tirzepatide (Mounjaro/Zepbound) continues to produce commercial and clinical wins. After a stellar second quarter earnings report and a $3 billion revenue guidance raise, Eli Lilly announced positive topline results from the SURMOUNT-1 trial where tirzepatide reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity/overweight compared to placebo. These results once again show the significant benefits of the incr ...